F2R and lung adenocarcinoma: Future studies with an orally available, potent, PAR-1 antagonist (SCH530348/vorapaxar; trade name, Zontivity) which was recently approved by the U.S. Food and Drug Administration to reduce the risk of heart attacks and stroke in high-risk patients [61], as well as αvβ6 integrin blocking agents, which are currently in clinical development [62], may offer therapeutic approaches for lung adenocarcinoma and potentially other cancers.